Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

Summary

This is a randomized, multicenter, open, controlled Post-Marketing Study. 272 early stage female breast cancer patients who were histopathology confirmed with adjuvant chemotherapy indications were enrolled in this study .The subjects will be randomly assigned to one of the two treatment groups at a 1: 1 ratio, and stratified by trastuzumab,age,baseline cardiac risk factors.

Timeline

Start

2017-09-01

Primary completion

2019-10-31

Completion

2020-10-31

Publications

• Tang L, He M, Geng C, Fan Z, Ling R, Qiao G, Cai L, Luo T, Jin F, Wang H, Zhang A, Zhang H, Zeng X, Wang X, Jiang M, Wang Z, Shao Z. Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial. Oncologist. 2025 Jun 4;30(6):oyaf101. doi: 10.1093/oncolo/oyaf101.

Drugs

Indications